肾肿块消融术中经静脉注射碘对比剂对术后eGFR的影响
本研究为双中心回顾性研究,纳入342例连续cT1a肾细胞癌消融患者,其中246例纳入分析。一个中心消融后常规行增强CT(对比剂组),另一中心不做(对照组)。多因素线性回归和倾向性评分匹配均显示,经静脉碘对比剂与eGFR下降无关联;消融本身导致eGFR轻度下降。
要点
- 消融后立即经静脉注射碘对比剂未显示对eGFR有独立影响(多因素回归系数1.91,95%CI -3.43-7.24,p=0.46)。
- 热消融本身可导致eGFR轻度下降(对照组70 vs 60 mL/min/1.73 m2,p<0.001;对比剂组75 vs 71 mL/min/1.73 m2,p=0.001)。
- 射频消融与微波消融后eGFR下降程度相似。
诊断标准与关键数值
- 对比剂组与对照组中位肿瘤直径分别为2.4 vs 2.5(p=0.23),RENAL肾脏测量评分分别为6 vs 6(p=0.92)。
- 对比剂组与对照组基线中位eGFR分别为70 vs 74 mL/min/1.73 m2(p=0.29)。
- 消融后eGFR下降:对照组70 vs 60 mL/min/1.73 m2(p<0.001);对比剂组75 vs 71 mL/min/1.73 m2(p=0.001)。
- 多因素线性回归显示经静脉碘对比剂与eGFR下降无关联(回归系数1.91,95%CI -3.43-7.24,p=0.46)。
- 1:1倾向性评分匹配模型显示经静脉碘对比剂与eGFR下降无关联(回归系数-0.33,95%CI -6.81-6.15,p=0.92)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the effect of intravenous iodinated contrast on estimated glomerular filtration rate (eGFR) when administered immediately after thermal ablation of clinically localized T1a (cT1a) renal cell carcinoma (RCC).
METHODS: This HIPAA-compliant, dual-center retrospective study was performed under a waiver of informed consent. Three hundred forty-two consecutive patients with cT1a biopsy-proven RCC were treated with percutaneous ablation between January 2010 and December 2017. Immediate post-ablation contrast-enhanced CT was the routine standard of care at one institution (contrast group), but not the other (control group). One-month pre- and 6-month post-ablation eGFR were compared using the Wilcoxon signed-rank test or the Kruskal-Wallis test. Multivariate linear regression was used to determine the effect of contrast on eGFR. A 1:1 propensity score matching was performed for all patients with a logistic model using patient, tumor, and procedural covariates.
RESULTS: In total, 246 patients (158 M; median age 69 years, IQR 62-74) were included. Median tumor diameter (2.4 vs 2.5, p = 0.23) and RENAL nephrometry scores (6 vs 6, p = 0.92), surrogates for ablation zone size, were similar. Baseline kidney function was similar for the control and contrast groups, respectively (median eGFR: 70 vs 74 mL/min/1.73 m2, p = 0.29). There was an expected mild decline in eGFR after ablation (control: 70 vs 60 mL/min/1.73 m2, p < 0.001; contrast: 75 vs 71 mL/min/1.73 m2, p = 0.001). Intravenous iodinated contrast was not associated with a decline in eGFR on multivariate linear regression (1.91, 95% CI - 3.43-7.24, p = 0.46) or 1:1 propensity score-matched model (- 0.33, 95% CI - 6.81-6.15, p = 0.92).
CONCLUSION: Intravenous iodinated contrast administered during ablation of cT1a RCC has no effect on eGFR.
KEY POINTS: • Intravenous iodinated contrast administered during thermal ablation of clinically localized T1a renal cell carcinoma has no effect on kidney function. • Thermal ablation of clinically localized T1a renal cell carcinoma results in a mild decline in kidney function. • A decline in kidney function is similar for radiofrequency and microwave ablation of clinically localized T1a renal cell carcinoma.
引用
- Curci NE, Triche BL, Abel EJ, et al. Effect of iodinated contrast material on post-operative eGFR when administered during renal mass ablation. Eur Radiol. 2021. PMID: 33492471. doi:10.1007/s00330-020-07613-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。